Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR3474)
Drug Name
SUVN-G3031
Synonyms LNXDUSQEXVQFGP-UHFFFAOYSA-N; UNII-65V47O9NOP; 65V47O9NOP; SCHEMBL12484542; N-[4-(1-Cyclobutyl piperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; 1394808-82-2
Indication Cognitive impairment [ICD11: 6D71] Phase 3 [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 373.5 Topological Polar Surface Area 54
Heavy Atom Count 27 Rotatable Bond Count 6
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 5
Cross-matching ID
PubChem CID
60151477
CAS Number
1394808-82-2
TTD Drug ID
D04KMP
Formula
C21H31N3O3
Canonical SMILES
C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)NC(=O)CN4CCOCC4
InChI
InChI=1S/C21H31N3O3/c25-21(16-23-12-14-26-15-13-23)22-17-4-6-19(7-5-17)27-20-8-10-24(11-9-20)18-2-1-3-18/h4-7,18,20H,1-3,8-16H2,(H,22,25)
InChIKey
LNXDUSQEXVQFGP-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
SUVN-G3031 Metabolite MA DM019121 N. A. Unclear - Unclear 1 [2]
SUVN-G3031 Metabolite MB DM019122 N. A. Unclear - Unclear 1 [2]
SUVN-G3031 Metabolite MC DM019123 N. A. Unclear - Unclear 1 [2]
SUVN-G3034 Metabolite MD DM015801
12277065
Oxidation - Dealkylation 1 [2]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR011579 SUVN-G3031 SUVN-G3031 Metabolite MA Unclear - Unclear CYP3A4 ... [2]
MR011580 SUVN-G3031 SUVN-G3031 Metabolite MB Unclear - Unclear Unclear [2]
MR011581 SUVN-G3031 SUVN-G3031 Metabolite MC Unclear - Unclear Unclear [2]
MR011582 SUVN-G3031 SUVN-G3034 Metabolite MD Oxidation - Dealkylation CYP3A4 ... [2]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
Monoamine oxidase type A (MAO-A) DME0044 Homo sapiens
AOFA_HUMAN
1.4.3.4
[2]
References
1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H(3)R) inverse agonist in clinical development for the treatment of narcolepsy

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.